Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;25(16-18):707-718.
doi: 10.1080/14622416.2025.2470613. Epub 2025 Feb 28.

Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions

Dorian Chastagner  1   2 , Hélène Arnion  1   3 , Clément Danthu  4 , Fatouma Touré  4 , Nicolas Picard  1   2   3
Affiliations
Review

Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions

Dorian Chastagner et al. Pharmacogenomics. 2024.

Abstract

Posttransplantation diabetes mellitus (PTDM) is a form of diabetes developed after solid organ or stem cell transplantation. This condition shares physiopathological traits with type 2 diabetes, including insulin resistance and β-cells dysfunction and its prevalence varies significantly based on the diagnostic criteria used. Immunosuppressive drugs directly contribute to PTDM risk through intricate impacts on glucose regulation, insulin secretion, and inflammation. In addition, modifiable and non-modifiable environmental risk factors are associated with the onset of this condition. This review aims to provide a comprehensive overview of the multifactorial nature of PTDM in order to highlight candidate genes and variants for pharmacogenetic research. An extensive literature search was conducted to identify studies on pharmacological and genetic factors influencing PTDM development. This review stresses the importance of understanding these interactions for improving PTDM management and underscores the need for further research to refine preventive approaches, ultimately enhancing patient outcomes post-transplantation.

Keywords: Solid-organ transplantation; adverse drug reaction; diabetes; hyperglycemia; immunosuppressive drugs; pharmacogenetics.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

    1. Veroux M, Tallarita T, Corona D, et al. Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Clin Dev Immunol. 2013;2013:496974. - PMC - PubMed
    1. Díaz-Molina B, Tavira B, Lambert JL, et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Transplant Proc. 2012;44(9):2635–2638. - PubMed
    1. Musavi Z, Azarpira N, Sangtarash MH, et al. Polymorphism of transcription factor-7-like 2 (TCF7L2) gene and New-onset diabetes after liver transplantation. Int J Organ Transplant Med. 2015;6(1):14–22. - PMC - PubMed
    1. Cen C, Fang H-X, Yu S-F, et al. Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation. Hepatobiliary Pancreat Dis Int. 2017;16(6):602–609. - PubMed
    1. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25(3):583–592. - PubMed

MeSH terms

Substances

LinkOut - more resources